Log in

Relevant bibliographies by topics / Methotrexate Testing / Journal articles

To see the other types of publications on this topic, follow the link: Methotrexate Testing.

Journal articles on the topic 'Methotrexate Testing'

Author: Grafiati

Published: 4 June 2021

Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Methotrexate Testing.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

KARWAKI, TANYA E., THOMAS K. HAZLET, and JENNIFER L. WILSON NORTON. "Lessons Learned in Developing and Testing a Methotrexate Case Study for Pharmacy Education." Cambridge Quarterly of Healthcare Ethics 29, no. 2 (March 11, 2020): 308–16. http://dx.doi.org/10.1017/s0963180119001099.

Full text

Abstract:

AbstractThis article describes the development, implementation, and evaluation of a complex methotrexate ethics case used in teaching a Pharmacy Law and Ethics course. Qualitative analysis of student reflective writings provided useful insight into the students’ experience and comfort level with the final ethics case in the course. These data demonstrate a greater student appreciation of different perspectives, the potential for conflict in communicating about such cases, and the importance of patient autonomy. Faculty lessons learned are also described, facilitating adoption of this methotrex

APA, Harvard, Vancouver, ISO, and other styles

2

Chernyshov, Pavel. "Testing for HIV prior to methotrexate administration. Is it an obligatory procedure?" International Journal of Dermatology 45, no. 8 (August 2006): 998–99. http://dx.doi.org/10.1111/j.1365-4632.2006.02746.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Satz, W., P. Torres, and J. W. Ufberg. "Is liver function testing necessary prior to methotrexate treatment for ectopic pregnancy?" Annals of Emergency Medicine 44, no. 4 (October 2004): S17. http://dx.doi.org/10.1016/j.annemergmed.2004.07.057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Jang, Ji-Hun, Seung-Hyun Jeong, and Yong-Bok Lee. "Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study." Pharmaceutics 12, no. 10 (October 16, 2020): 978. http://dx.doi.org/10.3390/pharmaceutics12100978.

Full text

Abstract:

Methotrexate, which is widely used in the treatment of cancer and immune-related diseases, has limitations in use because of its low bioavailability, short half-life, and tissue toxicity. Thus, in this study, a nano-sized water-in-oil-in-water (W/O/W) double emulsion containing methotrexate was prepared to enhance its lymphatic delivery and bioavailability. Based on the results from solubility testing and a pseudo-ternary diagram study, olive oil as the oil, Labrasol as a surfactant, and ethanol as a co-surfactant, were selected as the optimal components for the nanoemulsion. The prepared nano

APA, Harvard, Vancouver, ISO, and other styles

5

Eisenberger, M., S. Krasnow, S. Ellenberg, H. Silva, J. Abrams, V. Sinibaldi, D. Van Echo, and J. Aisner. "A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer." Journal of Clinical Oncology 7, no. 9 (September 1989): 1341–45. http://dx.doi.org/10.1200/jco.1989.7.9.1341.

Full text

Abstract:

Patients with recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) were stratified by performance status, extent of disease, and prior radiotherapy and subsequently randomized to receive carboplatin (CBDCA; Bristol-Myers, Wallingford, CT) administered intravenously (IV) monthly, initially at doses of 400 mg/m2 in combination with methotrexate (MTX) given IV weekly at doses of 40 mg/m2 or MTX alone at the same dose/schedule. Significant dose-limiting myelosuppression required CBDCA dose reductions to 300 mg/m2 and, subsequently, 200 mg/m2. Nonhematological toxicities we

APA, Harvard, Vancouver, ISO, and other styles

6

Gunawan, Prastiya Indra, and Darto Saharso. "A case of juvenile dermatomyositis responding to methotrexate and steroid." Bangladesh Journal of Medical Science 17, no. 4 (September 19, 2018): 675–77. http://dx.doi.org/10.3329/bjms.v17i4.38336.

Full text

Abstract:

A 4-year-old patient presented with skin rash and muscle weakness. She was diagnosed with juvenile dermatomyositis based on Bohan and Peter criteria as well as laboratory testing. She received steroid and combined with methotrexate. The treatment resulted in a good response.Bangladesh Journal of Medical Science Vol.17(4) 2018 p.675-677

APA, Harvard, Vancouver, ISO, and other styles

7

Bennett, James A., Steven M. Parnes, and Ronald C. DeConti. "Growth and Chemosensitivity of Human Head and Neck Cancers Implanted under the Kidney Capsule of Cyclosporine-Immunosuppressed Mice." Annals of Otology, Rhinology & Laryngology 98, no. 6 (June 1989): 455–60. http://dx.doi.org/10.1177/000348948909800612.

Full text

Abstract:

Thirty-seven of 54 human squamous cell head and neck carcinomas were grown successfully as first transplant generation xenografts under the kidney capsule of conventional mice immunosuppressed by daily treatment with 60 mg/kg of cyclosporine. Eighteen different tumors were evaluated for chemosensitivity to cis-diamminedichloroplatinum (cisplatin), 5-fluorouracil, and methotrexate. Thirty-nine percent of the tumors responded to cisplatin, 19% to 5-fluorouracil, and 33% to methotrexate. This assay response is consistent with the clinical response of human squamous head and neck carcinoma to thes

APA, Harvard, Vancouver, ISO, and other styles

8

Kavanaugh, Arthur, Ronald F. van Vollenhoven, Roy Fleischmann, Paul Emery, Iain Sainsbury, Stefan Florentinus, Su Chen, Benoît Guérette, Hartmut Kupper, and Josef S. Smolen. "Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis." Annals of the Rheumatic Diseases 77, no. 2 (November 16, 2017): 289–92. http://dx.doi.org/10.1136/annrheumdis-2017-211871.

Full text

Abstract:

ObjectivesTo compare responses in patients with early rheumatoid arthritis (RA) initially treated with the tumour necrosis factor inhibitor (TNFi) adalimumab+methotrexate (MTX) versus MTX monotherapy who may have continued receiving MTX or switched to adalimumab rescue therapy after inadequate response to MTX.MethodsOPTIMA enrolled MTX-naive patients with active RA for <1 year. This post hoc analysis determined the proportion of patients, stratified by initial treatment, who achieved 28-joint modified Disease Activity Score based on C reactive protein <3.2, normal function and/or no radi

APA, Harvard, Vancouver, ISO, and other styles

9

KOCHARLA, LAKSHMI, JANALEE TAYLOR, TRACEY WEILER, TRACY V. TING, MICHAEL LUGGEN, and HERMINE I. BRUNNER. "Monitoring Methotrexate Toxicity in Juvenile Idiopathic Arthritis." Journal of Rheumatology 36, no. 12 (November 16, 2009): 2813–18. http://dx.doi.org/10.3899/jrheum.090482.

Full text

Abstract:

Objective.To determine the frequency of laboratory abnormalities with methotrexate (MTX) use in patients with juvenile idiopathic arthritis (JIA); to identify potential risk factors for MTX toxicity requiring medical interventions; and to compare the frequency of liver function abnormalities in patients treated with MTX to those not treated with MTX.Methods.Results of MTX surveillance laboratory testing (SLT) available in clinical databases were reviewed for 588 children with JIA. Information on demographics, JIA features, and factors previously associated with increased frequency of SLT abnor

APA, Harvard, Vancouver, ISO, and other styles

10

Hilal, Talal, Alanna Maguire, Heidi E. Kosiorek, Lisa M. Rimsza, and Allison C. Rosenthal. "Clinical Features and Cell of Origin Subtyping Using Gene Expression Profiling in HIV-Negative Patients with Primary Central Nervous System Lymphoma." Blood 132, Supplement 1 (November 29, 2018): 2977. http://dx.doi.org/10.1182/blood-2018-99-110660.

Full text

Abstract:

Abstract Objectives: Primary central nervous system lymphoma (PCNSL) is a rare aggressive B-cell lymphoma, particularly in HIV-negative individuals, that represents a clinical challenge due to its location and lack of comprehensive molecular and biologic description. Histopathologic features are that of diffuse large B-cell lymphoma with expression of pan-B-cell markers as well as cell of origin (COO) germinal center B cell (GCB) and post-germinal center B cell (non-GCB) markers. Previous studies using immunohistochemistry (IHC) suggest that the majority of PCNSL cases are non-GCB. However, ge

APA, Harvard, Vancouver, ISO, and other styles

11

Kishor, Dr Kriti, Dr Debashish Mishra, Dr Siddharth Jain, Dr Nusrat Shafiq, Dr Varun Dhir, Dr Sanjay Jain, and Dr Shefali K. Sharma. "Prevalence Of Tuberculin Skin Test Positivity In Patients Of Early Rheumatoid Arthritis- Study from a tertiary care centre in North India." International Journal of Medical Research & Review 9, no. 2 (March 25, 2021): 120–26. http://dx.doi.org/10.17511/ijmrr.2021.i02.12.

Full text

Abstract:

Objective: To assess the prevalence of tuberculin skin test (TST) positivity in early rheumatoidarthritis patients (< 6months disease duration) using Tuberculin sensitivity testing in a TB endemiccountry. Method: Included in this cross-sectional study were 200 patients of early rheumatoidarthritis divided into three groups- treatment naïve, patients on methotrexate only andmethotrexate plus low dose corticosteroids. 1TU (0.1ml) of PPD RT-23 with tween 80 was injectedintradermally over the left forearm and the induration measured after 72 hours. For interpretation,Induration >10mm was tak

APA, Harvard, Vancouver, ISO, and other styles

12

Priest, Virginia L., Evan J. Begg, Sharon J. Gardiner, Christopher M. A. Frampton, Richard B. Gearry, Murray L. Barclay, David W. J. Clark, and Paul Hansen. "Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease." PharmacoEconomics 24, no. 8 (2006): 767–81. http://dx.doi.org/10.2165/00019053-200624080-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Mecoli, Christopher A., Nikolay G. Delev, and Clifton O. Bingham. "Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter?" Clinical Rheumatology 35, no. 12 (July 29, 2016): 3053–56. http://dx.doi.org/10.1007/s10067-016-3361-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Tseng, Li-Hui, Ming-Tseh Lin, John A. Hansen, Ted Gooley, Ji Pei, Anajane G. Smith, Emily G. Martin, Effie W. Petersdorf, and Paul J. Martin. "Correlation Between Disparity for the Minor Histocompatibility Antigen HA-1 and the Development of Acute Graft-Versus-Host Disease After Allogeneic Marrow Transplantation." Blood 94, no. 8 (October 15, 1999): 2911–14. http://dx.doi.org/10.1182/blood.v94.8.2911.420k21_2911_2914.

Full text

Abstract:

Results of a previous study suggested that recipient mismatching for the minor histocompatibility antigen HA-1 is associated with acute graft-versus-host disease (GVHD) after allogeneic marrow transplantation. In that study, most patients received either cyclosporine or methotrexate for GVHD prophylaxis, and a cytotoxic T-cell clone was used to test for HA-1 disparity. To facilitate large-scale testing, we developed a method that uses genomic DNA to identify HA-1 alleles. A retrospective study was conducted to correlate HA-1 disparity and the occurrence of acute GVHD in 237 HLA-A2–positive whi

APA, Harvard, Vancouver, ISO, and other styles

15

Westhovens, René, William F. C. Rigby, Désirée van der Heijde, Daniel W. T. Ching, William Stohl, Jonathan Kay, Arvind Chopra, et al. "Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial." Annals of the Rheumatic Diseases 80, no. 6 (January 15, 2021): 727–38. http://dx.doi.org/10.1136/annrheumdis-2020-219213.

Full text

Abstract:

Objectives To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure. Methods This 52-week, phase 3, multicentre, double-blind clinical trial (NCT02886728) evaluated once-daily oral filgotinib in 1252 patients with RA randomised 2:1:1:2 to filgotinib 200 mg with MTX (FIL200 +MTX), filgotinib 100 mg with MTX (FIL100 +MTX), filgotinib 200 mg monotherapy (FIL200), or MTX. The primary endpoint was proportion achieving 20% improvement in American College of Rheumatology criteri

APA, Harvard, Vancouver, ISO, and other styles

16

Sode, Jacob, Sophine B. Krintel, Anting Liu Carlsen, Merete L. Hetland, Julia S. Johansen, Kim Hørslev-Petersen, Kristian Stengaard-Pedersen, et al. "Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial." Journal of Rheumatology 45, no. 1 (November 15, 2017): 53–61. http://dx.doi.org/10.3899/jrheum.170266.

Full text

Abstract:

Objective.The aim was to identify plasma (i.e., cell-free) microRNA (miRNA) predicting antitumor necrosis and/or methotrexate (MTX) treatment response in patients enrolled in an investigator-initiated, prospective, double-blinded, placebo-controlled trial (The OPERA study,NCT00660647).Methods.We included 180 disease-modifying antirheumatic drug–naive patients with early rheumatoid arthritis (RA) randomized to adalimumab (ADA; n = 89) or placebo (n = 91) in combination with MTX. Plasma samples before and 3 months after treatment initiation were analyzed for 91 specific miRNA by quantitative rev

APA, Harvard, Vancouver, ISO, and other styles

17

Surguladze, David, Erik Corcoran, James Tonra, and Yiwen Li. "Synergistic Anti-Leukemic Effect of Combination Therapy with Anti-FLT3 Antibody IMC-EB10 and Methotrexate." Blood 112, no. 11 (November 16, 2008): 3964. http://dx.doi.org/10.1182/blood.v112.11.3964.3964.

Full text

Abstract:

Abstract FLT3 is a class III receptor tyrosine kinase overexpressed by blast cells in approximately 90% of acute myeloid leukemia and acute lymphoid leukemia (ALL) patients. Recent findings testing a small molecule FLT3 inhibitor (PKC412) in combination with eight conventional antileukemic agents, reported that methotrexate in particular did not combine well with PKC412 against leukemia cells (Furukawa, Y. et al., Leukemia 2007, 21: 1005–1014). IMC-EB10 is a fully human neutralizing antibody that binds FLT3 with high affinity (Kd 158 pM) and blocks FLT3 ligand binding to FLT3 (IC50 ~10 nM), le

APA, Harvard, Vancouver, ISO, and other styles

18

Krull, Kevin R., Yin Ting Cheung, Wei Liu, Slim Fellah, Wilburn E. Reddick, Tara M. Brinkman, Cara Kimberg, et al. "Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia." Journal of Clinical Oncology 34, no. 22 (August 1, 2016): 2644–53. http://dx.doi.org/10.1200/jco.2015.65.4574.

Full text

Abstract:

Purpose To examine associations among methotrexate pharmacodynamics, neuroimaging, and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy-only protocol. Patients and Methods This longitudinal study linked pharmacokinetic assays collected during therapy to neurocognitive and brain imaging outcomes during long-term follow-up. A total of 218 (72.2%) of 302 eligible long-term survivors were recruited for outcome studies when they were more than 5 years post-diagnosis and older than 8 years of age. At long-term follow-up,

APA, Harvard, Vancouver, ISO, and other styles

19

Thurmond, Robin L., Andrew Greenspan, Waldemar Radziszewski, Xie L. Xu, Ye Miao, Bin Chen, TingTing Ge, et al. "Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies." Journal of Rheumatology 43, no. 9 (July 15, 2016): 1637–42. http://dx.doi.org/10.3899/jrheum.160164.

Full text

Abstract:

Objective.To assess toreforant (selective histamine H4 receptor antagonist) in active rheumatoid arthritis (RA).Methods.In a phase IIa, double-blind, placebo-controlled test, 86 patients were randomized (2:1) to once-daily toreforant 100 mg or placebo for 12 weeks. In phase IIb, double-blind, placebo-controlled, dose-range–finding evaluations, 272 patients were randomized (1:1:1:1) to once-daily placebo or toreforant 3/10/30 mg. Primary efficacy endpoints for both studies were Week 12 changes in 28-joint Disease Activity Score–C-reactive protein (DAS28-CRP).Results.Phase IIa testing was termin

APA, Harvard, Vancouver, ISO, and other styles

20

Schuh, Michael J., and Sheena Crosby. "Methotrexate Central Nervous System Toxicity Identified in a Pharmacogenomics Pharmacist Consult Patient." Senior Care Pharmacist 34, no. 9 (October 1, 2019): 595–99. http://dx.doi.org/10.4140/tcp.n.2019.595.

Full text

Abstract:

OBJECTIVE: To report a possible pharmacogenomics (PGx)-related, cognitive dysfunction, adverse drug reaction from methotrexate (MTX) that may be multifactorial in origin. SUMMARY: The patient subject is a 76-year-old Caucasian female of Russian ancestry suffering from rheumatoid arthritis and treated with MTX who presented to the diagnostic and consultative physician service in a medical clinic with advancing cognitive dysfunction, manifesting as memory loss, dizziness, and confusion. Components of this possible adverse drug reaction (ADR) may include ancestry, pharmacogenomics (PGx) character

APA, Harvard, Vancouver, ISO, and other styles

21

Owen, S. A., M. Lunt, S. L. Hider, I. N. Bruce, A. Barton, and W. Thomson. "Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort." Arthritis & Rheumatism 62, no. 12 (November 30, 2010): 3827–29. http://dx.doi.org/10.1002/art.27754.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Bauer, Bruce, Po-Huang Chyou, Erik J. Stratman, and Clayton Green. "Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy." JAMA Dermatology 153, no. 10 (October 1, 2017): 977. http://dx.doi.org/10.1001/jamadermatol.2017.2083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Mitxelena-Iribarren, Oihane, Sara Lizarbe-Sancha, Jay Campisi, Sergio Arana, and Maite Mujika. "Different Microfluidic Environments for In Vitro Testing of Lipid Nanoparticles against Osteosarcoma." Bioengineering 8, no. 6 (June 4, 2021): 77. http://dx.doi.org/10.3390/bioengineering8060077.

Full text

Abstract:

The use of lipid nanoparticles as biodegradable shells for controlled drug delivery shows promise as a more effective and targeted tumor treatment than traditional treatment methods. Although the combination of target therapy with nanotechnology created new hope for cancer treatment, methodological issues during in vitro validation of nanovehicles slowed their application. In the current work, the effect of methotrexate (MTX) encapsulated in different matrices was evaluated in a dynamic microfluidic platform. Effects on the viability of osteosarcoma cells in the presence of recirculation of ce

APA, Harvard, Vancouver, ISO, and other styles

24

Mazewski, Claire, Guolian Kang, Stewart Kellie, Jeffrey Gossett, Sarah Leary, Bryan Li, Paul Aridgides, et al. "MBCL-34. EFFICACY OF METHOTREXATE (MTX) ACCORDING TO MOLECULAR SUB-TYPE IN YOUNG CHILDREN WITH MEDULLOBLASTOMA (MB): A REPORT FROM CHILDREN’S ONCOLOGY GROUP PHASE III TRIAL ACNS0334." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii396. http://dx.doi.org/10.1093/neuonc/noaa222.510.

Full text

Abstract:

Abstract ACNS0334, a Phase 3 trial, compared outcomes of children &lt;36 months treated with intensive chemotherapy +/-high-dose methotrexate. Nodular-desmoplastic M0-stage MB were excluded. Treatment included 3 induction cycles (cyclophosphamide/etoposide/vincristine/cisplatin+/-mtx) and 3 consolidation cycles (carboplatin/thiotepa with stem cell rescue). Radiation (RT) was at physician discretion. Molecular sub-typing was by DNA-methylation. Log-rank testing was used to compare survival differences. Molecular sub-typing of 38 MB identified 11 Sonic Hedgehog (SHH), 25 Group 3 (GP3), 2 Gro

APA, Harvard, Vancouver, ISO, and other styles

25

Sundbaum, Johanna Karlsson, Eva Baecklund, Niclas Eriksson, Pär Hallberg, Hugo Kohnke, and Mia Wadelius. "MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis." Pharmacogenomics 21, no. 5 (April 2020): 337–46. http://dx.doi.org/10.2217/pgs-2019-0186.

Full text

Abstract:

Aims: To investigate whether variants of MTHFR, TYMS and SLCO1B1 are associated with ALT elevation in rheumatoid arthritis patients starting methotrexate (MTX). Patients & methods: Clinical and laboratory data were collected from the start of MTX treatment. Genotyping of MTHFR, TYMS and SLCO1B1 was performed. Univariate and multiple logistic regression were used for statistical analysis. Results: 34 out of 369 patients experienced ALT >1.5 × ULN less than 6 months from start. MTHFR A1298C (rs1801131) was nominally associated with an ALT >1.5 × ULN within 6 months after the start of M

APA, Harvard, Vancouver, ISO, and other styles

26

Kapetanovic, M. C., T. Saxne, J. A. Nilsson, and P. Geborek. "Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients." Rheumatology 46, no. 4 (October 13, 2006): 608–11. http://dx.doi.org/10.1093/rheumatology/kel366.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Stiebitz, Sebastian, Tasslem von Streng, and Moritz Strickler. "Delayed diagnosis of rheumatoid arthritis in an elderly patient presenting with weakness and desolation." BMJ Case Reports 14, no. 2 (February 2021): e237251. http://dx.doi.org/10.1136/bcr-2020-237251.

Full text

Abstract:

We describe the case of an 81-year-old man who presented with unspecific symptoms of desolation and general weakness, which led to a delayed diagnosis of rheumatoid arthritis (RA). The patient had not received any previous treatment as he had not been in contact with medical services for several years prior to hospital admission. This enabled advanced disease manifestations to develop, including peripheral neuropathy with distal paraparesis, lethargy and weight loss. These signs and symptoms were later recognised as extra-articular manifestations of RA and classical features of RA were less pr

APA, Harvard, Vancouver, ISO, and other styles

28

Haddad, Anis, Olfa Zoukar, Houda Mhabrich, Awatef Hajjeji, and Raja Faleh. "Postpartum Treatment of a Herniation of the Anterior Uterine Wall due to Remains of Placenta Increta." Case Reports in Obstetrics and Gynecology 2018 (October 30, 2018): 1–6. http://dx.doi.org/10.1155/2018/5921495.

Full text

Abstract:

In recent years, the incidence of placenta accreta and associated complications has increased significantly. The authors report the case of a pregnant woman in the 5th month of pregnancy for premature rupture of the membranes. The placenta was inserted low. The evolution was marked spontaneous work followed by the expulsion of the fetus. The delivery of the placenta was haemorrhagic and incomplete. Ultrasonic testing showed a placental fragment integrated in the thickness of the myometrium. Conservative treatment with methotrexate was published a few days later and MRI showed that the anterior

APA, Harvard, Vancouver, ISO, and other styles

29

Alten, R. E., C. Zerbini, S. Jeka, F. Irazoque, F. Khatib, P. Emery, A. Bertasso, M. Rabbia, and J. P. Caulfield. "Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy." Annals of the Rheumatic Diseases 69, no. 2 (April 8, 2009): 364–67. http://dx.doi.org/10.1136/ard.2008.104802.

Full text

Abstract:

Objective:To determine the efficacy and safety of pamapimod in adult patients with active rheumatoid arthritis (RA) who had an inadequate clinical response to methotrexate (MTX).Methods:Patients receiving stable doses of MTX were randomised to one of six dose groups and received 12 weeks of double-blind pamapimod (up to 300 mg once daily) or matching placebo. The primary efficacy measure was the proportion of patients with ⩾20% improvement in RA based on the American College of Rheumatology criteria (ACR20) at 12 weeks. Secondary measures were ACR50, Disease Activity Score (DAS)/European Leagu

APA, Harvard, Vancouver, ISO, and other styles

30

Cheung, Yin Ting, Raja B. Khan, Wei Liu, Tara M. Brinkman, Michelle N. Edelmann, Wilburn E. Reddick, Deqing Pei, et al. "Biomarkers of brain injury and neurologic outcomes in children treated with chemotherapy for acute lymphoblastic leukemia (ALL)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 10521. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.10521.

Full text

Abstract:

10521 Background: Little is known about neurotoxic mechanisms associated with chemotherapy in children with ALL. Cerebrospinal fluid (CSF) biomarkers of brain injury may provide insight into this process. Methods: 235 patients (51% male; mean [SD] age diagnosed 6.8 [4.7] years) treated on a chemotherapy only protocol provided CSF samples following diagnosis and through consolidation. CSF was assayed for biomarkers of myelin degradation (myelin basic protein [MBP]), neuronal damage (nerve growth factor [NGF], total-Tau [T-Tau]) and astrogliosis (glial fibrillary acidic protein [GFAP]). Leukoenc

APA, Harvard, Vancouver, ISO, and other styles

31

Guillermo Prieto Eibl, Pilar, Appaji Rayi, Iyad Alnahhas, Pierre Giglio, and Narendranath Epperla. "NCMP-12. RAPIDLY PROGRESSIVE NEUROPATHIES AS THE SOLE PRESENTATION OF NEUROLYMPHOMATOSIS." Neuro-Oncology 22, Supplement_2 (November 2020): ii125. http://dx.doi.org/10.1093/neuonc/noaa215.523.

Full text

Abstract:

Abstract Neurolymphomatosis (NL) is a rare and challenging entity characterized by hematological neoplastic infiltration of the peripheral nervous system. Only 40% of the cases have malignant cells on CSF sampling. We present a 52-year-old Caucasian male with primary refractory diffuse large B-cell lymphoma (DLBCL) who relapsed within 3 months of achieving complete remission to R-CHOP. First, he experienced right tongue numbness and lumbar pain. Initial MRI of the face, brain and entire spine, and CSF analysis were unremarkable. Three weeks later, he noticed left facial numbness, dysphonia, an

APA, Harvard, Vancouver, ISO, and other styles

32

Mititelu, Roxana, Larry W. Cheung, and Denis Sasseville. "Cutaneous polyarteritis nodosa and concurrent pseudoxanthoma elasticum–like phenotype: A case report." SAGE Open Medical Case Reports 8 (January 2020): 2050313X2095311. http://dx.doi.org/10.1177/2050313x20953110.

Full text

Abstract:

We report a unique case of a patient presenting with histologically confirmed pseudoxanthoma elasticum–like phenotype and cutaneous polyarteritis nodosa. Cardiac, gastroenterological, and ophthalmologic evaluations were within normal limits. Genetic evaluation was pertinent for absent ABCC6, ENPP1, and GGCX mutations and a normal array comparative genomic hybridization. Extensive workup revealed skin-limited cutaneous polyarteritis nodosa, and further genetic testing for ADA2 deficiency was negative. The cutaneous polyarteritis nodosa lesions had an excellent response to hydroxychloroquine and

APA, Harvard, Vancouver, ISO, and other styles

33

Berkowitz, Eran, Ella Arnon, Alona Yaakobi, Yuval Cohen, and Beatrice Tiosano. "IgG4-Related Disease Presenting as Isolated Scleritis." Case Reports in Ophthalmological Medicine 2017 (2017): 1–4. http://dx.doi.org/10.1155/2017/4876587.

Full text

Abstract:

A rare case of IgG4-related disease (IgG4-RD) manifesting as nodular scleritis is presented in a 20-year-old female. Patient complained of left eye pain and redness for one week. Ocular examination together with ancillary testing led to the diagnosis of nodular scleritis. Since the patient did not show apparent improvement after one week of systemic steroidal treatment, she underwent a biopsy of the affected area revealing histopathological characteristics of IgG4-RD. Long-term treatment with corticosteroids and a steroid-sparing agent (methotrexate) led to significant improvement in signs and

APA, Harvard, Vancouver, ISO, and other styles

34

Waber, Deborah P., Jennifer Turek, Lori Catania, Kristen Stevenson, Philippe Robaey, Ivonne Romero, Heather Adams, et al. "Neuropsychological Outcomes From a Randomized Trial of Triple Intrathecal Chemotherapy Compared With 18 Gy Cranial Radiation As CNS Treatment in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 95-01." Journal of Clinical Oncology 25, no. 31 (November 1, 2007): 4914–21. http://dx.doi.org/10.1200/jco.2007.10.8464.

Full text

Abstract:

Purpose We evaluated late neuropsychological toxicity in children treated for standard-risk acute lymphoblastic leukemia (ALL) who were randomly assigned to receive either cranial radiation therapy (CRT) with double intrathecal (IT) chemotherapy or intensive triple IT chemotherapy (no CRT) as CNS-directed therapy. Patients and Methods Between 1996 and 2000, 164 children with standard-risk ALL treated on Dana-Farber Cancer Institute Consortium Protocol 95-01 were randomly assigned to receive either 18 Gy CRT delivered in twice daily fractions (0.9 Gy) with double IT therapy (methotrexate and cy

APA, Harvard, Vancouver, ISO, and other styles

35

Shu, Jenny, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui, Carol Hitchon, J. Carter Thorne, Diane Tin, Edward C. Keystone, and Janet E. Pope. "Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort." Journal of Rheumatology 42, no. 11 (September 1, 2015): 2023–28. http://dx.doi.org/10.3899/jrheum.150260.

Full text

Abstract:

Objective.Anticitrullinated protein antibody (ACPA) is as sensitive as, but more specific than, rheumatoid factor (RF) and is detected earlier in rheumatoid arthritis (RA). Although part of the RA classification criteria, ACPA testing is not routinely paid for/accessible in all jurisdictions. The effect of missing ACPA testing was studied to determine whether failure to perform ACPA testing could cause a care gap in early inflammatory arthritis.Methods.Nearly 2000 patients (n = 1998) recruited to an early inflammatory arthritis cohort were allocated into 3 groups: (1) seropositive (either RF+

APA, Harvard, Vancouver, ISO, and other styles

36

Mazewski, Claire, Guolian Kang, Stewart Kellie, Jeffrey Gossett, Sarah Leary, Bryan Li, Paul Aridgides, et al. "ETMR-20. IMPACT OF HIGH DOSE CHEMOTHERAPY WITH AND WITHOUT METHOTREXATE (MTX) ON OUTCOME OF PATIENTS WITH EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs): A REPORT FROM CHILDREN’S ONCOLOGY GROUP PHASE III TRIAL ACNS0334." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii327. http://dx.doi.org/10.1093/neuonc/noaa222.223.

Full text

Abstract:

Abstract Infant embryonal brain tumors comprise a spectrum of histologic and molecular entities including medulloblastoma (MB) and tumors collectively called CNS PNET’s, including supratentorial PNET (sPNET), pineoblastoma and other less common histologic entities. Non-MB embryonal tumors, historically considered high risk disease, were included in ACNS0334, A Children’s Oncology Group prospective phase III trial which compared efficacy of an induction regimen with and without methotrexate combined with high dose chemotherapy and stem cell rescue; no radiation was mandated. Molecular testing p

APA, Harvard, Vancouver, ISO, and other styles

37

Triano, Matthew J., William D. Haberstroh, Abhishek Lenka, and Sean A. Whelton. "Relapsed granulomatosis with polyangiitis with panhypopituitarism." BMJ Case Reports 14, no. 1 (January 2021): e237774. http://dx.doi.org/10.1136/bcr-2020-237774.

Full text

Abstract:

A man in his early 60s with a medical history of granulomatosis with polyangiitis (GPA) in remission for two decades without maintenance therapy presented with non-specific complaints of profound fatigue and 40-pound weight loss. He was seronegative for antinuclear antibodies and cytoplasmic antineutrophilic antibodies, but erythrocyte sedimentation rate and C reactive protein levels were elevated. Endocrinological testing revealed adrenal insufficiency, hypogonadism, hypothyroidism and diabetes insipidus. An MRI of the head revealed extensive sinonasal inflammation eroding through the floor o

APA, Harvard, Vancouver, ISO, and other styles

38

Giri, Bhupendra Raj, Jung Suk Kim, Jong Hyuck Park, Sung Giu Jin, Kyeong Soo Kim, Fakhar ud Din, Han Gon Choi, and Dong Wuk Kim. "Improved Bioavailability and High Photostability of Methotrexate by Spray-Dried Surface-Attached Solid Dispersion with an Aqueous Medium." Pharmaceutics 13, no. 1 (January 16, 2021): 111. http://dx.doi.org/10.3390/pharmaceutics13010111.

Full text

Abstract:

Low aqueous solubility and poor bioavailability are major concerns in the development of oral solid-dosage drug forms. In this study, we fabricated surface-attached solid dispersion (SASD) to enhance the solubility, bioavailability, and photostability of methotrexate (MTX), a highly lipophilic and photo-unstable drug. Several MTX-loaded SASD formulations were developed for spray-drying using water as the solvent, and were investigated for their aqueous solubility and dissolution kinetics. An optimized ternary SASD formulation composed of MTX/ sodium carboxymethyl cellulose (Na-CMC)/sodium laur

APA, Harvard, Vancouver, ISO, and other styles

39

Taylor, S. G., E. Applebaum, J. L. Showel, M. Norusis, L. D. Holinger, J. C. Hutchinson, A. K. Murthy, and D. D. Caldarelli. "A randomized trial of adjuvant chemotherapy in head and neck cancer." Journal of Clinical Oncology 3, no. 5 (May 1985): 672–79. http://dx.doi.org/10.1200/jco.1985.3.5.672.

Full text

Abstract:

Ninety-five patients with squamous cell carcinoma of the head and neck were entered into a randomized study testing a two-week course of induction chemotherapy with methotrexate and leucovorin given prior to regional therapy. In addition, following regional therapy, patients randomized to chemotherapy were to receive similar methotrexate courses every three months for one year. Poor tolerance to this regimen after radiation and surgery led to a change in the chemotherapy following regional therapy to a combination of Adriamycin (Adria Laboratories, Columbus, Ohio) and cisplatin every three wee

APA, Harvard, Vancouver, ISO, and other styles

40

Ali, Zain, Joanna Chyu, Mhd Hasan Almekdash, and Mohamad M. Al-Rahawan. "ALL-058: Evaluating Urine pH and Specific Gravity: A Single-Center Experience Comparing Different Urine Testing Methods in Children Receiving High-Dose Methotrexate." Clinical Lymphoma Myeloma and Leukemia 21 (September 2021): S265—S266. http://dx.doi.org/10.1016/s2152-2650(21)01647-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Bnatig, Fahad, Leen Raddaoui, Talal Hijji, and Lina El Kibbi. "Mixed Cryoglobulinemia in a Patient with Juvenile Idiopathic Arthritis." Case Reports in Rheumatology 2019 (June 6, 2019): 1–2. http://dx.doi.org/10.1155/2019/5858106.

Full text

Abstract:

Cryoglobulinemia is a rare illness of cryoglobulin accumulation in the blood which can typically present with arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral neuropathy. It is classified as mixed cryoglobulinemia when cryoglobulins contain more than one immune component such as IgM rheumatoid factor and polyclonal IgG. Typically, it presents in the setting of clonal hematologic disease, viral infection, or certain connective tissue diseases. Herein, we report the case of a 24-year-old man diagnosed and treated as mixed cryoglobulinemia in the setting of juvenile idiopathic

APA, Harvard, Vancouver, ISO, and other styles

42

MORI, SHUNSUKE, ISAMU CHO, and MINEHARU SUGIMOTO. "A Followup Study of Asymptomatic Carriers ofPneumocystis jiroveciDuring Immunosuppressive Therapy for Rheumatoid Arthritis." Journal of Rheumatology 36, no. 8 (June 16, 2009): 1600–1605. http://dx.doi.org/10.3899/jrheum.081270.

Full text

Abstract:

Objective.To examine the preventive effects of prophylaxis againstPneumocystis jiroveci-induced pneumonia (PCP) in patients receiving immunosuppressive therapy for rheumatoid arthritis (RA) who are colonized by this organism.Methods.We performed molecular testing by polymerase chain reaction (PCR) forP. jirovecion induced sputum or bronchoalveolar lavage fluids of 82 patients with RA. During primary prophylaxis, asymptomatic carriers of this organism were examined by high-resolution computed tomography and PCR every 2 weeks. RA patients who had developed PCP received PCR tests every week. Once

APA, Harvard, Vancouver, ISO, and other styles

43

Bouri, S., J. Geldof, J. Willsmore, S. Donnelly, S. Gabe, and A. Hart. "P583 The prevalence of side effects to immunomodulators and biologics in patients with Crohn’s disease intestinal failure compared with Crohn’s disease without intestinal failure." Journal of Crohn's and Colitis 14, Supplement_1 (January 2020): S488—S489. http://dx.doi.org/10.1093/ecco-jcc/jjz203.711.

Full text

Abstract:

Abstract Background Treatment of Crohn’s disease (CD) involves medications and surgery but experiencing medication side effects (SE) limits medical options. The aim of this study was to compare SE experienced by patients with CD and intestinal failure (CD-IF) vs. CD without IF as this may contribute to a higher surgical requirement. Methods A single tertiary centre retrospective analysis was performed on CD-IF patients on parenteral nutrition due to short-bowel syndrome vs. small bowel CD without IF. Patients with CD without IF were selected from consecutive clinics who lived in the local catc

APA, Harvard, Vancouver, ISO, and other styles

44

Ali, Zain, Joanna Chyu, Mhd Hasan Almekdash, and Mohamad M. Al-Rahawan. "Poster: ALL-058: Evaluating Urine pH and Specific Gravity: A Single-Center Experience Comparing Different Urine Testing Methods in Children Receiving High-Dose Methotrexate." Clinical Lymphoma Myeloma and Leukemia 21 (September 2021): S206. http://dx.doi.org/10.1016/s2152-2650(21)01289-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Claytor, Jennifer, Omar Viramontes, Stephanie Conner, Kwun Wah Wen, Kendall Beck, Timothy J. Henrich, Peter Chin-Hong, Peter Chin-Hong, and Michael J. Peluso. "969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S514. http://dx.doi.org/10.1093/ofid/ofaa439.1155.

Full text

Abstract:

Abstract Background Despite the risks of immunosuppression, recommendations regarding screening for HIV infection prior to initiation of biologic therapies targeting common autoimmune disorders, including inflammatory bowel disease (IBD) and inflammatory arthritides, are limited. Few cases of patients started on biologics while living with undiagnosed HIV have been reported. Methods We report 3 cases of patients initiated on biologics in the absence of recent or concurrent HIV screening who developed refractory disease or unanticipated complications and were later found to have undiagnosed chr

APA, Harvard, Vancouver, ISO, and other styles

46

Alrajhi, Saad, Pascale Germain, Myriam Martel, Peter Lakatos, Talat Bessissow, Talal Al-Taweel, and Waqqas Afif. "Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease." Intestinal Research 18, no. 3 (July 30, 2020): 306–14. http://dx.doi.org/10.5217/ir.2019.00116.

Full text

Abstract:

Background/Aims: Latent tuberculosis screening is mandatory prior to initiating anti-tumor necrosis factor (anti-TNF) medications. Guidelines recommend interferon-gamma release assays (IGRA) as first line screening method for the general population. Studies provided conflicting evidence on IGRA and tuberculin skin test (TST) performance in inflammatory bowel disease (IBD) patients. We assessed test concordance and the effects of immunosuppression on their performance in IBD patients.Methods: We searched MEDLINE, Embase and Cochrane databases (2011–2018) for studies testing TST and IGRA in IBD.

APA, Harvard, Vancouver, ISO, and other styles

47

Kager, Leo, Meyling H. Cheok, Wenjian Yang, Gianluigi Zaza, Ching-Hon Pui, James R. Downing, Mary V. Relling, and William E. Evans. "Folate Pathway Gene Expression Differs in Genetic Subtypes of Acute Lymphoblastic Leukemia and Influences Methotrexate Pharmacodynamics." Blood 104, no. 11 (November 16, 2004): 452. http://dx.doi.org/10.1182/blood.v104.11.452.452.

Full text

Abstract:

Abstract Methotrexate (MTX) is an essential treatment component for acute lymphoblastic leukemia (ALL). The ability of leukemia cells to accumulate MTX in its polyglutamylated form (MTXPG) is recognized as an important determinant of its antileukemic effect. We measured in vivo MTXPG accumulation in leukemia cells from 101 children with ALL, and established that blasts of B-lineage ALL with either the TEL-AML1 (n=24 patients, median 911, range 338 to 5906 pmol/109 blasts) or E2A-PBX1 gene fusion (n=5, median 553, range 364 to 800 pmol/109 blasts) or T-lineage ALL (n=14, median 572, range 284 t

APA, Harvard, Vancouver, ISO, and other styles

48

DeLuca, Marie, Philip A. Gruppuso, and Edward J. Wing. "Successful treatment of Takayasu’s arteritis in a HIV positive adult patient with long term follow up." Case Reports in Internal Medicine 3, no. 4 (August 16, 2016): 14. http://dx.doi.org/10.5430/crim.v3n4p14.

Full text

Abstract:

Although vasculitides occur in patients with HIV, only 4 previous cases of Takayasu’s arteritis (TA) have been reported in HIVpatients. We describe the first case of TA in an HIV positive patient with successful treatment and long term follow up. A38-year-old woman who was HIV positive for the last 5 years on antiretroviral medications presented with increasing pain in herleft arm. Blood pressure and pulse were unrecordable in that arm. Laboratory testing revealed hemoglobin 7.9 g/dl, CRP 98.8 mg/L, CD4 675 cells/μl and HIV viral load < 48 copies/ml. Both MRA and standard angiography demons

APA, Harvard, Vancouver, ISO, and other styles

49

Fernando, Suran L., Therese Boyle, Annika Smith, and John D. E. Parratt. "The Successful Use of Infliximab in a Relapsing Case of Susac’s Syndrome." Case Reports in Neurological Medicine 2020 (June 10, 2020): 1–6. http://dx.doi.org/10.1155/2020/9317232.

Full text

Abstract:

Susac’s syndrome is a rare and debilitating disease characterized by the triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. All manifestations may not be clinically apparent at presentation resulting in delayed diagnosis. Early recognition of the syndrome may prevent disease sequelae such as permanent cognitive, visual, and hearing loss. We present such a case of Susac’s syndrome that was also refractory to conventionally prescribed combination of immunosuppressive treatments including high-dose potent corticosteroids, intravenous cyclophosphamide, metho

APA, Harvard, Vancouver, ISO, and other styles

50

Jones, S. E., J. C. Dean, L. A. Young, and S. E. Salmon. "The human tumor clonogenic assay in human breast cancer." Journal of Clinical Oncology 3, no. 1 (January 1985): 92–97. http://dx.doi.org/10.1200/jco.1985.3.1.92.

Full text

Abstract:

The human tumor clonogenic assay (HTCA) was evaluated in 407 fresh samples of breast cancer from 288 patients. Seventy samples were inadequate for testing. Adequate in vitro growth for drug testing (greater than 30 colonies/plate) was obtained in 91 (27%) of the 337 viable samples, inadequate growth for drug evaluation (5 to 30 colonies/plate) in 17%, and no colony formation (less than 5 colonies/plate) in 56%. Operationally defining a greater than or equal to 50% inhibition of colony formation as in vitro drug sensitivity, the in vitro response rates to 12 anticancer drugs tested against ten

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!